Dekabank Deutsche Girozentrale Reduces $127K in Bicycle Therapeutics plc ($BCYC)
Key Points
- Dekabank Deutsche Girozentrale changed its Bicycle Therapeutics plc ($BCYC) stake by 100% last quarter, cutting to 0 shares.
- Wall Street's consensus rating on $BCYC is Buy and an average price target of $9.50.
- $BCYC last traded around $4.24.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Dekabank Deutsche Girozentrale reduced its position in Bicycle Therapeutics plc ($BCYC), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of Bicycle Therapeutics plc after selling 30,000 shares during the quarter.
Bicycle Therapeutics plc Stock Up 1.0%
Shares of Bicycle Therapeutics plc ($BCYC) traded around $4.24 on Saturday, up 1.0% for the day.
Bicycle Therapeutics plc Earnings
Analysts Set New Price Targets
About Bicycle Therapeutics plc
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Get Bicycle Therapeutics plc alerts
New 13F filings, insider trades, and analyst moves on $BCYC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.